Xarelto 15mg (rivaroxaban): Uses, Dosage & Side Effects

What it's for (Indications)

Rivaroxaban is indicated for the prevention and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk.
It is used for the prophylaxis of DVT following elective hip or knee replacement surgery.
Rivaroxaban is also indicated for the prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Furthermore, it is used for the prophylaxis of atherothrombotic events following an acute coronary syndrome (ACS) with increased cardiac biomarkers, and for the reduction in the risk of major adverse cardiovascular events in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) in combination with aspirin.
It may also be used for the prophylaxis of VTE in acutely ill medical patients at risk for thromboembolic complications.

Dosage Information

Type	Guideline
Standard	Rivaroxaban is administered orally. Nonvalvular Atrial Fibrillation: 15 mg or 20 mg once daily, taken with food, preferably with evening meals. Treatment of DVT and/or PE: Initially, 15 mg orally twice daily with food for the first 21 days, followed by 20 mg orally once daily with food for the remaining treatment duration (typically at least 3 months for DVT/PE). Reduction in Recurrence of DVT and/or PE: 10 mg once daily, with or without food, after at least 6 months of standard anticoagulant treatment. Prophylaxis of DVT Following Hip or Knee Replacement Surgery: 10 mg orally once daily, with or without food, typically for 2 to 5 weeks. Prophylaxis of VTE in Acutely Ill Medical Patients: 10 mg once daily, with or without food, for a total recommended duration of 31 to 39 days. Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD): 2.5 mg orally twice daily, with or without food, in combination with aspirin (75–100 mg) once daily. Administration: Tablets should be swallowed whole with water and not chewed. If needed, tablets can be crushed and mixed with a small amount of applesauce; this mixture should be consumed immediately, followed by a meal. Do not exceed the prescribed dose. Storage: Store at room temperature (approximately 25°C), avoiding damp or moist areas, and close tightly after each use.

Type

Guideline

Standard

Rivaroxaban is administered orally. Nonvalvular Atrial Fibrillation: 15 mg or 20 mg once daily, taken with food, preferably with evening meals. Treatment of DVT and/or PE: Initially, 15 mg orally twice daily with food for the first 21 days, followed by 20 mg orally once daily with food for the remaining treatment duration (typically at least 3 months for DVT/PE). Reduction in Recurrence of DVT and/or PE: 10 mg once daily, with or without food, after at least 6 months of standard anticoagulant treatment. Prophylaxis of DVT Following Hip or Knee Replacement Surgery: 10 mg orally once daily, with or without food, typically for 2 to 5 weeks. Prophylaxis of VTE in Acutely Ill Medical Patients: 10 mg once daily, with or without food, for a total recommended duration of 31 to 39 days. Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD): 2.5 mg orally twice daily, with or without food, in combination with aspirin (75–100 mg) once daily. Administration: Tablets should be swallowed whole with water and not chewed. If needed, tablets can be crushed and mixed with a small amount of applesauce; this mixture should be consumed immediately, followed by a meal. Do not exceed the prescribed dose. Storage: Store at room temperature (approximately 25°C), avoiding damp or moist areas, and close tightly after each use.

Safety & Warnings

Common Side Effects

Common adverse reactions include bleeding (which is the most common, manifesting as hematoma, epistaxis/nosebleed, hemoptysis/coughing blood, or bloody stools), anemia, nausea, vomiting, gastrointestinal upset, headache, dizziness, hypotension, fever, edema (swelling), fatigue, renal (kidney) impairment, and serious skin reactions.
Other reported side effects include back pain, bowel or bladder dysfunction, leg weakness, and cough.

Serious Warnings

Black Box Warning: Premature discontinuation of rivaroxaban increases the risk of thrombotic events. Spinal/epidural hematoma, which can result in long-term or permanent paralysis, may occur with neuraxial anesthesia or spinal puncture.
Bleeding Risk: Rivaroxaban significantly increases the risk of bleeding.
Caution is advised in patients with active pathological bleeding, a history of gastrointestinal ulceration, uncontrolled hypertension, bleeding disorders, or in those with artificial heart valves.
Concomitant use with NSAIDs, other antiplatelets (e.
g.
, clopidogrel), aspirin, or other blood thinners is not recommended due to a heightened risk of bleeding.
Thrombotic Events: Premature discontinuation of rivaroxaban, especially in patients with nonvalvular atrial fibrillation, significantly increases the risk of thrombotic events, including stroke.
The effect of the drug generally wears off within 24 hours after discontinuation.
Spinal/Epidural Hematoma: There is a risk of spinal or epidural hematoma with neuraxial anesthesia (spinal/epidural puncture), which can result in long-term or permanent paralysis.
Lumbar puncture and spinal anesthesia should be avoided during rivaroxaban therapy.
Drug Interactions: Inform healthcare providers about all concomitant medications, especially HIV drugs (protease inhibitors), certain antifungals, tuberculosis medications, St.
John’s wort, or seizure medications, as these can affect rivaroxaban's efficacy or increase toxicity.
Hepatic/Renal Impairment: Exercise caution in patients with liver disease (e.
g.
, cirrhosis) or kidney disease (renal impairment).
Surgical Procedures: Rivaroxaban should be stopped at least 24 hours before any surgical intervention.

How it Works (Mechanism of Action)

Rivaroxaban is a highly selective direct inhibitor of Factor Xa (FXa). Its anticoagulant activity does not require a cofactor such as Anti-thrombin III. Rivaroxaban inhibits both free FXa and prothrombinase activity. By inhibiting FXa, rivaroxaban effectively decreases thrombin generation, which in turn indirectly inhibits platelet aggregation induced by thrombin.